Close this search box.


These materials are available for nonprofit educational use. This repository is allowed by copyright disclaimer under title 17, Appendix E, section 107 of the United States Copyright Act. Under this statute, allowance is made for “fair use” for purposes such as criticism, comment, news reporting, teaching, scholarship, and research. As defined, fair use specifically applies to this repository.

  • Degreef I, Degreef I, Tejpar S DSL. Recurrence After Surgery For Dupuytren’s Disease: A Randomised Controlled Trial With Double Blinding, Combining Segmental Fasciectomy With Placebo Or With Neo-Adjuvant Oral Tamoxifen. 2009. (PDF)
  • Degreef I, Tejpar S, Sciot R, De Smet L. High-dosage tamoxifen as neoadjuvant treatment in minimally invasive surgery for Dupuytren disease in patients with a strong predisposition toward fibrosis: a randomized controlled trial. J Bone Joint Surg Am. 2014 Apr 16;96(8):655–62. (PDF)
  • Dellê H, Rocha JRC, Cavaglieri RC, Vieira JM, Malheiros DM a C, Noronha IL. Antifibrotic effect of tamoxifen in a model of progressive renal disease. J Am Soc Nephrol. 2012 Jan;23(1):37–48. (PDF)
  • Hu D, Hughes MA, Cherry GW. Topical tamoxifen–a potential therapeutic regime in treating excessive dermal scarring? Br J Plast Surg. 1998 Sep;51(6):462–9. (PDF)
  • Ilg, M. M., et al. (2020). “Phosphodiesterase Type 5 Inhibitors and Selective Estrogen Receptor Modulators Can Prevent But Not Reverse Myofibroblast Transformation in Peyronie’s Disease.” J Sex Med 17(10): 1848-1864. (PDF)
  • Kuhn MA, Wang X, Payne WG, Ko F, Robson MC. Tamoxifen decreases fibroblast function and downregulates TGF(beta2) in Dupuytren’s affected palmar fascia. J Surg Res. 2002/04/02 ed. 2002 Apr;103(2):146–52. (PDF)
  • Pujol H, Girault J, Rouanet P, Fournier S, Grenier J, Simony J, et al. Phase I study of percutaneous 4-hydroxy-tamoxifen with analyses of 4-hydroxy-tamoxifen concentrations in breast cancer and normal breast tissue. Cancer Chemother Pharmacol. 1995 Jan;36(6):493–8. (PDF)
  • Timmons MJ. Fibromatosis, desmoids, fibroblasts, and tamoxifen. Br J Plast Surg. 1994 Jul;47(5):378–80. (PDF)
  • van Bommel EFH, Hendriksz TR, Huiskes AWLC, Zeegers AGM. Brief communication: tamoxifen therapy for nonmalignant retroperitoneal fibrosis. Ann Intern Med. 2006 Jan 17;144(2):101–6. (PDF)